<DOC>
	<DOCNO>NCT02231164</DOCNO>
	<brief_summary>The present trial investigate efficacy safety nintedanib combination docetaxel compare placebo combination docetaxel patient stage IIIB/IV recurrent NSCLC adenocarcinoma histology failure first-line platinum-based chemotherapy .</brief_summary>
	<brief_title>LUME-Columbus : Nintedanib Plus Docetaxel Advanced Non-small Cell Lung Cancer With Translational Research</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Male female patient least 18 year age Histologically confirm , adenocarcinoma lung , failure first line platinumbased chemotherapy . Exclusion criterion : More one prior line chemotherapy ( i.e. , 2nd 3rd line chemotherapy ) advance and/or metastatic ( stage III B IV NSCLC ) recurrent disease . Patients know positive activate Epidermal Growth Factor Receptor ( EGFR ) mutation anaplastic lymphoma kinase ( ALK ) translocation Previous therapy vascular endothelial growth factor ( VEGF ) VEGFR inhibitor ( bevacizumab ) docetaxel treatment NSCLC time Prior monotherapy EGFR inhibitor except maintenance therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>